§ 01

What Are SNRIs?

Duloxetine

Duloxetine

Mechanism of Action Diagram

Serotonin-norepinephrine reuptake inhibitors (SNRIs) are antidepressants that also have analgesic effects in some chronic pain conditions. They work by increasing serotonin (5-HT) and norepinephrine (NE) in descending pain-modulating pathways that influence how nociceptive signals are processed in the spinal cord and brain.

Compared with tricyclic antidepressants (TCAs), SNRIs are more selective and usually produce fewer anticholinergic and cardiac side effects. That does not make them side-effect-free, but it often makes them easier to use in older adults and in patients who do not tolerate TCAs well.

Duloxetine is often chosen because it addresses both mood symptoms and the central amplification component that may accompany chronic pain.

Duloxetine is FDA-approved for chronic musculoskeletal pain, fibromyalgia, and diabetic peripheral neuropathy, which is why it is often the most evidence-supported SNRI for persistent musculoskeletal pain. Milnacipran is FDA-approved for fibromyalgia and offers a more NE-weighted profile. For myofascial pain syndrome, SNRIs are usually most relevant when central sensitization, widespread pain, depression, anxiety, or fibromyalgia overlap are present.

§ 02

Mechanism of Action

SNRIs are used in pain medicine because they enhance neurotransmission in descending pain-modulating pathways. Each SNRI has a slightly different selectivity profile, which helps explain why the drugs are not interchangeable in every patient.

Mechanism of Action

Mechanism of Action

Mechanism Diagram
01

Serotonin (5-HT) Reuptake Inhibition

SNRIs block the serotonin transporter (SERT) on presynaptic neurons, reducing reuptake of 5-HT from the synaptic cleft. This increases serotonin availability in descending pain-modulating pathways originating from brainstem serotonergic nuclei. Enhanced serotonergic transmission likely contributes to spinal pain modulation, while also influencing mood, sleep, and overall symptom burden in chronic pain patients.

02

Norepinephrine (NE) Reuptake Inhibition

SNRIs also block the norepinephrine transporter (NET), increasing norepinephrine availability in descending inhibitory pathways from the locus coeruleus. Noradrenergic activity at alpha-2 adrenoceptors in the spinal cord is widely considered an important contributor to analgesia. This is one reason SNRIs with more clinically meaningful NE activity often perform better for pain than medications that act mainly as serotonin reuptake inhibitors.

03

Duloxetine Specificity

Duloxetine provides clinically useful dual serotonin and norepinephrine reuptake inhibition and is often considered the best-studied SNRI for chronic musculoskeletal pain. It does not significantly bind to muscarinic, histaminergic, or alpha-1 adrenergic receptors, which helps explain why its side-effect profile is generally cleaner than that of tricyclic antidepressants.

04

Venlafaxine Specificity

Venlafaxine has dose-dependent pharmacology. At lower doses it behaves more like a serotonin-predominant agent, while clinically meaningful norepinephrine reuptake inhibition becomes more relevant at higher doses, typically above 150 mg/day. This is why lower-dose venlafaxine may be less compelling for pain than higher-dose therapy.

05

Milnacipran Specificity

Milnacipran is more norepinephrine-selective than duloxetine and venlafaxine. That profile may make it attractive in some patients with pain, fatigue, and fibromyalgia-like presentations, although response remains individualized rather than predictable from receptor ratios alone.

06

Central Sensitization Modulation

In chronic myofascial pain, persistent nociceptive input may contribute to central sensitization and impaired descending inhibition. SNRIs are used in part because they may strengthen descending modulatory pathways and reduce amplified pain processing, especially when widespread pain, sleep disruption, mood symptoms, or fibromyalgia overlap are present.

07

Comparison with TCAs

Compared with tricyclic antidepressants (TCAs), SNRIs are more selective and generally carry less anticholinergic burden, less sedation, and lower cardiac toxicity risk. TCAs may still help some pain phenotypes because they have broader pharmacology, but SNRIs are often preferred when tolerability and safety are priorities.

§ 03

Individual Drug Profiles

Duloxetine (Cymbalta)

Most Studied for Pain

5-HT > NE

Dose for Pain30-60 mg once daily
Half-Life12 hours
Max Dose120 mg/day (additional benefit above 60 mg is often limited)
TitrationStart 30 mg x 1 week, then increase to 60 mg if tolerated

FDA Approvals

Major depressive disorder (MDD)Generalized anxiety disorder (GAD)FibromyalgiaChronic musculoskeletal painDiabetic peripheral neuropathy

Key Evidence

  • Among the best-studied SNRIs for chronic musculoskeletal pain
  • Randomized trials support benefit in chronic low back pain and osteoarthritis-related pain populations
  • Also supported in fibromyalgia and other centrally amplified pain presentations
  • Often chosen first when pain and depression/anxiety overlap
  • Best evidence in related chronic pain conditions rather than isolated myofascial pain syndrome trials

Common Side Effects

  • Nausea (common early side effect, often transient over 1-2 weeks)
  • Dry mouth, drowsiness, constipation
  • Dizziness, fatigue
  • Decreased appetite

Metabolism & Drug Interactions

Hepatic via CYP1A2 (primary) and CYP2D6. Strong CYP1A2 inhibitors such as fluvoxamine or ciprofloxacin may increase levels. CYP2D6 interactions can also matter in selected patients.

Warnings & Precautions

  • Avoid or use very cautiously in significant hepatic impairment or substantial alcohol use
  • Rare but important liver injury has been reported — monitor when clinically indicated
  • Contraindicated with MAOIs (14-day washout required)
Best For →Best For Persistent myofascial pain with central sensitization features, fibromyalgia overlap, or concurrent depression/anxiety. Often the SNRI most clinicians consider first for chronic musculoskeletal pain.

Venlafaxine (Effexor XR)

Dose-Dependent Analgesia

5-HT predominant at low dose; more dual action at higher dose

Dose for Pain150-225 mg once daily (extended-release)
Half-Life5 hours (parent) / 11 hours (active metabolite)
Max Dose225 mg/day (higher doses are used more often in psychiatry than pain practice)
TitrationStart 37.5-75 mg x 1 week, then increase gradually toward 150+ mg if needed

FDA Approvals

Major depressive disorder (MDD)Generalized anxiety disorder (GAD)Social anxiety disorderPanic disorderNOT FDA-approved for any pain indication

Key Evidence

  • Pain-related evidence is stronger at higher doses where norepinephrine reuptake inhibition becomes more relevant
  • Some support exists in neuropathic and headache-related pain conditions
  • Less directly studied in chronic musculoskeletal pain than duloxetine
  • Sometimes considered when mood/anxiety treatment is also needed and duloxetine is not suitable

Common Side Effects

  • Nausea, dry mouth, dizziness, insomnia
  • Blood pressure increase becomes more relevant at higher doses — monitor
  • Sweating, particularly nocturnal
  • Discontinuation symptoms can be pronounced and often require slow tapering

Metabolism & Drug Interactions

Hepatic via CYP2D6 (primary) to active metabolite O-desmethylvenlafaxine, with CYP3A4 as a minor pathway. CYP2D6 phenotype and drug interactions can influence response.

Warnings & Precautions

  • Monitor blood pressure regularly, especially above 150 mg/day
  • Discontinuation syndrome can be substantial — do not stop abruptly
  • Contraindicated with MAOIs
  • Use caution in uncontrolled hypertension
Best For →Best For Patients needing SNRI treatment with concurrent depression/anxiety or headache-predominant pain patterns, especially when higher-dose therapy is acceptable and blood pressure is monitored.

Milnacipran (Savella)

More NE-Selective

NE > 5-HT

Dose for Pain50 mg BID (twice daily)
Half-Life6-8 hours
Max Dose100 mg BID (200 mg/day)
Titration12.5 mg once daily x 1 day, then 12.5 mg BID x 2 days, then 25 mg BID x 4 days, then 50 mg BID

FDA Approvals

Fibromyalgia (FDA-approved)NOT approved for MDD in the United States (approved for depression in Europe and Japan)

Key Evidence

  • Strongest formal evidence is in fibromyalgia rather than isolated myofascial pain
  • May help pain, fatigue, and global symptoms in fibromyalgia populations
  • Reasonable option when fibromyalgia-myofascial overlap is suspected
  • Often considered when duloxetine is ineffective or poorly tolerated

Common Side Effects

  • Nausea (common), headache, constipation
  • Increased heart rate, palpitations
  • Hot flushes, hyperhidrosis
  • Dysuria or urinary hesitancy in some patients
  • BID dosing is less convenient than once-daily alternatives

Metabolism & Drug Interactions

Predominantly renal excretion with minimal CYP involvement. This makes milnacipran less susceptible to many hepatic drug-drug interactions and can be useful in more complex polypharmacy settings.

Warnings & Precautions

  • May increase blood pressure and heart rate — monitor
  • Contraindicated with MAOIs
  • Use caution in renal impairment (reduce dose in significant impairment)
  • Cost and availability can be limiting factors
Best For →Best For Fibromyalgia-myofascial overlap, patients with hepatic concerns, or patients taking multiple hepatically metabolized drugs where a cleaner interaction profile is valuable.

Desvenlafaxine (Pristiq)

Fewer CYP Issues

5-HT > NE

Dose for Pain50-100 mg once daily
Half-Life11 hours
Max Dose100 mg/day (higher doses usually add side effects more than benefit)
TitrationStart at 50 mg daily; some patients may be trialed at 100 mg

FDA Approvals

Major depressive disorder (MDD)NOT FDA-approved for any pain indication

Key Evidence

  • Less directly studied for pain than duloxetine or even venlafaxine
  • Often chosen for pharmacokinetic simplicity rather than stronger pain evidence
  • Useful when CYP2D6 interaction concerns make venlafaxine less attractive
  • Pain-related use is usually extrapolated from class effect rather than direct robust trials

Common Side Effects

  • Nausea, dizziness, insomnia, hyperhidrosis
  • Discontinuation symptoms still occur, though often less dramatically than with venlafaxine
  • Elevated blood pressure possible
  • Constipation, dry mouth

Metabolism & Drug Interactions

Primarily conjugation (UGT) with minimal CYP3A4 metabolism and little CYP2D6 dependence. This makes it one of the cleaner SNRI options for drug-interaction purposes.

Warnings & Precautions

  • Monitor blood pressure
  • Taper gradually when discontinuing
  • Contraindicated with MAOIs
  • Limited direct pain evidence — best used when interaction profile is the main reason for choosing it
Best For →Best For Patients with complex medication lists, CYP2D6 interaction concerns, or depression with milder pain where a simpler interaction profile is especially useful.
§ 04

Clinical Evidence for myofascial pain

Moderate EvidenceDirect RCTs remain limited; most support comes from related pain conditions

Dedicated randomized trials for isolated myofascial pain syndrome are limited. The rationale for SNRI use comes mainly from stronger evidence in chronic musculoskeletal pain, fibromyalgia, and chronic low back pain — conditions that often overlap with or contain a myofascial component.

Skljarevski et al. (2010)

Duloxetine demonstrated statistically significant pain reduction in chronic low back pain populations, supporting its broader role in chronic musculoskeletal pain. This evidence is relevant to myofascial pain because many low back pain cohorts include a meaningful myofascial component.

Chappell et al. (2009)

Duloxetine showed clinically meaningful improvement in chronic musculoskeletal pain populations including osteoarthritis-related pain. Analgesic benefit often appeared before the full antidepressant effect, supporting a direct pain-modulating mechanism.

Clauw et al. (2008)

Milnacipran significantly improved pain outcomes in fibromyalgia compared with placebo, reinforcing the rationale for SNRI use in centrally amplified musculoskeletal pain states.

Mease et al. (2009)

A large fibromyalgia trial confirmed milnacipran benefit for pain, function, and global improvement, with somewhat greater effect at higher doses for some outcomes.

Lunn et al. (2014) — Cochrane Review

Systematic review data support duloxetine for fibromyalgia and some neuropathic pain conditions, with moderate-quality evidence for clinically meaningful benefit in a subset of patients.

Expert Consensus — myofascial pain Extrapolation

Dedicated randomized controlled trials for isolated myofascial pain syndrome remain limited. Even so, many clinicians extrapolate from chronic musculoskeletal pain, fibromyalgia, and chronic low back pain data when central sensitization, widespread pain, or mood symptoms are part of the picture.

Modest benefit

a subset of patients achieves clinically meaningful improvement in related chronic pain studies

1-2 Week Onset

partial benefit may appear early, though fuller response takes longer

Central Sensitization

often where SNRIs fit best clinically
§ 05

Side Effects & Management

SNRIs are often better tolerated than TCAs, but side effects still matter — especially during the first days to weeks of treatment. Early counseling about nausea, dizziness, sweating, sleep changes, and tapering helps adherence considerably.

§ 06

SNRIs vs TCAs vs Gabapentinoids

SNRIs vs TCAs vs Gabapentinoids

SNRIs vs TCAs vs Gabapentinoids

Comparison Chart
Category
SNRIsTCAsGabapentinoids

Efficacy for Musculoskeletal Pain

Moderate. Best direct evidence for duloxetine in chronic musculoskeletal pain and fibromyalgia-related pain.
Moderate to strong in some chronic pain syndromes, especially neuropathic presentations, but often limited by tolerability.
More useful when neuropathic features are prominent; generally less convincing for pure myofascial or non-neuropathic musculoskeletal pain.

Side Effect Burden

Low to moderate. Nausea is the most common early problem. Usually less anticholinergic and less sedating than TCAs.
Higher. Anticholinergic effects, sedation, weight gain, and cardiac concerns are more prominent.
Moderate. Sedation, dizziness, weight gain, edema, and cognitive slowing are common concerns.

Cost (US, approximate)

Usually low for generics such as duloxetine and venlafaxine; milnacipran may be more expensive depending on coverage.
Very low in generic form.
Generally low for gabapentin; pregabalin may cost more depending on coverage and formulation.

Evidence Level for myofascial pain

Moderate indirect support. Stronger evidence exists for related chronic musculoskeletal and fibromyalgia conditions than for isolated myofascial pain syndrome.
Moderate indirect support with long clinical tradition but fewer modern MPS-specific trials.
Moderate for neuropathic pain, weaker for isolated myofascial pain.

Best Candidate

Central sensitization, widespread pain, mood symptoms, fibromyalgia overlap, or TCA intolerance.
Patients with neuropathic features, insomnia-predominant pain, or cost sensitivity who can tolerate the side effects.
Patients with neuropathic pain features, sleep disruption, or anxiety where sedation is not a major problem.

Drug Interactions

Moderate. Duloxetine has meaningful CYP interactions; serotonergic interactions also matter.
High. Multiple CYP interactions, additive QT or anticholinergic issues, and overdose toxicity matter.
Low CYP burden, but additive CNS depression with opioids, alcohol, or benzodiazepines remains important.

Safety in Overdose

Safer than TCAs overall, though venlafaxine overdose can still be clinically significant.
Higher risk, including serious cardiac and neurologic toxicity in overdose.
Usually relatively safe alone, though risk increases when combined with other sedatives.
§ 07

Practical Prescribing for myofascial pain

Initial Selection

Duloxetine is often the first SNRI considered for persistent myofascial or musculoskeletal pain. Milnacipran may be preferred when fibromyalgia overlap is prominent or hepatic concerns matter. Venlafaxine may be considered when migraine or broader psychiatric indications coexist, while desvenlafaxine may be useful when CYP2D6 interaction concerns are a major issue.

Titration Protocol

Duloxetine: start 30 mg once daily for about 1 week, then increase to 60 mg if tolerated. Milnacipran: gradual step-up over several days toward 50 mg BID. Venlafaxine XR: often starts at 37.5-75 mg daily and increases gradually toward 150+ mg when pain benefit is the goal. Slow titration usually improves tolerability.

Monitoring During Titration

Monitor for nausea, dizziness, insomnia, sweating, and blood pressure effects. Check blood pressure at baseline and again during titration, especially with venlafaxine or milnacipran. Assess mood and suicidality in younger patients. Consider liver monitoring when duloxetine is used in patients with meaningful hepatic risk factors.

Efficacy Assessment

Some benefit may appear within 1-2 weeks, but fuller assessment often requires 4-8 weeks at a therapeutic dose. Use pain scores, functional measures, sleep, and global improvement rather than pain intensity alone. A 30% pain reduction is often considered clinically meaningful, but function matters at least as much as the number.

Inadequate Response

If duloxetine 60 mg is inadequate after an adequate trial, options may include increasing the dose, switching within class, adding a medication for a neuropathic or sleep component, or reconsidering whether the patient needs a more multimodal non-pharmacologic plan. Refractory pain should also prompt re-evaluation of diagnosis and contributing mechanisms.

Duration & Discontinuation

There is no single universal treatment duration. Many patients remain on therapy for months, and some longer, depending on symptom recurrence, function, and side effects. When discontinuing, taper gradually over at least several weeks; venlafaxine often requires an especially slow taper. Never stop an SNRI abruptly unless medically necessary and supervised.
§ 08

Quick Reference: Choosing an SNRI

Start with Duloxetine if...

  • You want the best-studied SNRI for chronic musculoskeletal pain
  • There is chronic pain plus depression or anxiety
  • Central sensitization is suspected
  • Fibromyalgia overlap is possible
  • Once-daily dosing is preferred

Switch to Milnacipran if...

  • Duloxetine is not tolerated or not effective enough
  • Fibromyalgia features are prominent
  • Hepatic concerns make a renally cleared option more appealing
  • Polypharmacy makes CYP interactions more concerning

Consider Venlafaxine if...

  • Concurrent migraine prophylaxis is relevant
  • The patient already uses venlafaxine for psychiatric reasons
  • Higher-dose SNRI therapy is acceptable
  • Blood pressure can be monitored reliably

Consider Desvenlafaxine if...

  • CYP2D6 drug interactions are problematic
  • A simpler interaction profile is especially important
  • Depression is primary and pain is present but not the only target
  • Other SNRIs are less suitable because of metabolism concerns
Key Takeaways

  1. Duloxetine is often the SNRI most commonly considered first for persistent musculoskeletal pain because it has the strongest direct evidence in related pain conditions.

  2. SNRIs may reduce pain by enhancing descending inhibitory serotonergic and noradrenergic pathways, not only by treating depression.

  3. Noradrenergic activity appears to be especially relevant for analgesia, which is one reason higher-dose venlafaxine and more NE-selective agents may behave differently from lower-dose serotonin-predominant treatment.

  4. SNRIs are often most useful when central sensitization, widespread pain, sleep disruption, depression/anxiety, or fibromyalgia overlap are part of the clinical picture.

  5. Compared with TCAs, SNRIs usually offer a cleaner side-effect profile and lower overdose risk, though TCAs may still help some patients more.

  6. Venlafaxine generally needs higher doses to meaningfully engage the norepinephrine component relevant to pain treatment.

  7. Milnacipran is a reasonable alternative when duloxetine is not tolerated or when hepatic issues make a more renally cleared option appealing.

  8. Adequate trial duration matters. Partial benefit may appear within 1 to 2 weeks, but fuller assessment usually requires several weeks at a therapeutic dose.

  9. Discontinuation should be gradual — especially with venlafaxine, where withdrawal symptoms can be particularly prominent.

  10. SNRIs work best as part of a multimodal plan that also addresses sleep, movement, trigger point management, ergonomics, and stress-related perpetuating factors.